Tmunity Therapeutics

United States
South Weldon, North Carolina, United States, 19106

Company profile

Tmunity Therapeutics company profile

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.

Business identity

Phone number
215-966-1600
Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
19106
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
4
Total equity funding
$220M
Last funding
Series B / $75M / 2019-10-31
Last equity funding
Series B / $75M
Investors
11
Lead investors
1
Founders
6
Articles
27
Exited on
2022-12-20

Founders and investors

Founders

Anne ChewBruce BlazarBruce LevineCarl JuneJames RileyYangbing Zhao

Lead investors

Andreessen Horowitz

Investors

Andreessen HorowitzGilead SciencesKleiner PerkinsLilly Asia VenturesWestlake Village BioPartners